These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 11763155)

  • 21. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease.
    Ghoreschi K; Thomas P; Breit S; Dugas M; Mailhammer R; van Eden W; van der Zee R; Biedermann T; Prinz J; Mack M; Mrowietz U; Christophers E; Schlöndorff D; Plewig G; Sander CA; Röcken M
    Nat Med; 2003 Jan; 9(1):40-6. PubMed ID: 12461524
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proteasome inhibition reduces superantigen-mediated T cell activation and the severity of psoriasis in a SCID-hu model.
    Zollner TM; Podda M; Pien C; Elliott PJ; Kaufmann R; Boehncke WH
    J Clin Invest; 2002 Mar; 109(5):671-9. PubMed ID: 11877475
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of different targeting agents in the photolysis of interleukin-2 receptor bearing cells.
    Linares R; Pacheco JR; Good TA
    J Photochem Photobiol B; 2004 Dec; 77(1-3):17-26. PubMed ID: 15542358
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Requirement of high-affinity IL-2-IL-2R interaction for T cell anergy induction.
    Hayashi RJ; Kanagawa O
    Int Immunol; 2006 May; 18(5):645-51. PubMed ID: 16574670
    [TBL] [Abstract][Full Text] [Related]  

  • 25. From laboratory to clinic: rationale for biologic therapy.
    Mehlis S; Gordon KB
    Dermatol Clin; 2004 Oct; 22(4):371-7, vii-viii. PubMed ID: 15450333
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation of psoriasis activity with abundance of CD25+CD8+ T cells: conditions for cloning T cells from psoriatic plaques.
    Kohlmann WM; Urban W; Sterry W; Foerster J
    Exp Dermatol; 2004 Oct; 13(10):607-12. PubMed ID: 15447720
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Considerations when initiating psoriasis patients on biologic therapy.
    Zeichner JA
    J Drugs Dermatol; 2012 May; 11(5 Suppl):s11-4. PubMed ID: 22644771
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Beneficial clinical effects of cyclosporin A on severe psoriasis and its dissociation from serum concentration of soluble interleukin-2 receptor, soluble interleukin-6 receptor, soluble CD14 antigen, soluble intercellular adhesion molecule-1, and soluble vascular cell adhesion molecule-1.
    Yamamoto T; Kimura K; Katayama I; Koyano T; Mamada A; Miyazaki K; Irimajiri T; Furuse Y; Nishioka K
    Arch Dermatol Res; 1996 Dec; 289(1):57-9. PubMed ID: 9017138
    [No Abstract]   [Full Text] [Related]  

  • 29. [Prescribing immunosuppressive and immunomodulatory drugs in psoriasis].
    Kemula M; Bachelez H
    Rev Prat; 2004 Jan; 54(1):56-9. PubMed ID: 15049602
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Psoriasis--recent advances in understanding its pathogenesis and treatment.
    Krueger G; Ellis CN
    J Am Acad Dermatol; 2005 Jul; 53(1 Suppl 1):S94-100. PubMed ID: 15968269
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Etanercept in psoriasis treatment.
    Pietrzak A; Chodorowska G; Urban J; Roliński J; Pietrzak B
    Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):222-6. PubMed ID: 15314989
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug delivery and formulations for the topical treatment of psoriasis.
    Su YH; Fang JY
    Expert Opin Drug Deliv; 2008 Feb; 5(2):235-49. PubMed ID: 18248321
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New biologics for psoriasis and psoriatic arthritis.
    Rozenblit M; Lebwohl M
    Dermatol Ther; 2009; 22(1):56-60. PubMed ID: 19222517
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interleukin 4 or cytokine antagonists? Time to change the search for novel psoriasis therapies.
    Röcken M
    Dermatology; 2010 Aug; 221(1):27-9. PubMed ID: 20587989
    [No Abstract]   [Full Text] [Related]  

  • 35. Does the basal lamina contain interleukin 2 receptors? Observations in emerging psoriasis vulgaris lesions.
    Laub R; Fiebig H; Wohlrab W; Taube KM
    Dermatol Monatsschr; 1988; 174(6):308-11. PubMed ID: 3264794
    [No Abstract]   [Full Text] [Related]  

  • 36. New psoriasis drug tackles T cells.
    Health News; 2003 Apr; 9(4):8-9. PubMed ID: 12710397
    [No Abstract]   [Full Text] [Related]  

  • 37. The IL-2/IL-2 receptor system: a target for rational immune intervention.
    Waldmann TA
    Trends Pharmacol Sci; 1993 May; 14(5):159-64. PubMed ID: 8212311
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic basis of psoriasis vulgaris and its pharmacogenetic potential.
    Ameen M
    Pharmacogenomics; 2003 May; 4(3):297-308. PubMed ID: 12718720
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunotherapy for psoriasis: from serendipity to selectivity.
    Griffiths CE
    Lancet; 2002 Jan; 359(9303):279-80. PubMed ID: 11830192
    [No Abstract]   [Full Text] [Related]  

  • 40. Disease models--one size does not fit all.
    Kemp K
    Drug Discov Today; 2010 Mar; 15(5-6):161-2. PubMed ID: 20096803
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.